The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Open accessAbstract
Angelman syndrome is a single-gene disorder characterized by intellectual disability, developmental delay, behavioural uniqueness, speech impairment, seizures and ataxia. It is caused by maternal deficiency of the imprinted gene UBE3A, encoding an E3 ubiquitin ligase. All patients carry at least one copy of paternal UBE3A, which is intact but silenced by a nuclear-localized long non-coding RNA, UBE3A antisense transcript (UBE3A-ATS). Murine Ube3a-ATS reduction by either transcription termination or topoisomerase I inhibition has been shown to increase paternal Ube3a expression. Despite a clear understanding of the disease-causing event in Angelman syndrome and the potential to harness the intact paternal allele to correct the disease, no gene-specific treatment exists for patients. Here we developed a potential therapeutic intervention for Angelman syndrome by reducing Ube3a-ATS with antisense oligonucleotides (ASOs). ASO treatment achieved specific reduction of Ube3a-ATS and sustained unsilencing of paternal Ube3a in neurons in vitro and in vivo. Partial restoration of UBE3A protein in an Angelman syndrome mouse model ameliorated some cognitive deficits associated with the disease. Although additional studies of phenotypic correction are needed, we have developed a sequence-specific and clinically feasible method to activate expression of the paternal Ube3a allele.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822bead0 · Cited by 1,452
UBE3A/E6-AP mutations cause Angelman syndrome
Kishino, T., Lalande, M., & Wagstaff, J. (1997) · Nature Genetics · doi:10.1038/ng0197-70 · Cited by 1,298
De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R.-J., Jiang, Y.-H., Benton, C. S., Rommens, J. M., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0197-74 · Cited by 856
Self-citationJiang, Y.-H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G., Sweatt, J. D., & Beaudet, A. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80596-6 · Cited by 852 · cited 1×
“All the animals of WT, Ube3aKO/+ [15], and Ube3a+/YFP [12] were kept on C57BL/6 background and housed under the standard conditions in a pathogen-free mouse facility.”
MethodSelf-citationKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationAlbrecht, U., Sutcliffe, J. S., Cattanach, B. M., Beechey, C. V., Armstrong, D., Eichele, G., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0997-75 · Cited by 583
Self-citationLagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.-R., Jiang, J., Watt, A. T., Chun, S., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 561
Self-citationAntisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Topoisomerases facilitate transcription of long genes linked to autism
King, I. F., Yandava, C. N., Mabb, A. M., Hsiao, J. S., Huang, H.-S., Pearson, B. L., Calabrese, J. M., Starmer, J., Parker, J. S., Magnuson, T., et al. (2013) · Nature · doi:10.1038/nature12504 · Cited by 438
Dindot, S. V., Antalffy, B. A., Bhattacharjee, M. B., & Beaudet, A. L. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm288 · Cited by 418
Self-citationTopoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
Huang, H.-S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Lee, H.-M., Chen, X., et al. (2012) · Nature · doi:10.1038/nature10726 · Cited by 387
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Clinical and genetic aspects of Angelman syndrome
Williams, C. A., Driscoll, D. J., & Dagli, A. I. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181def138 · Cited by 311
An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript
Rougeulle, C., Cardoso, C., Fontés, M., Colleaux, L., & Lalande, M. (1998) · Nature Genetics · doi:10.1038/ng0598-15 · Cited by 298
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Self-citationChamberlain, S. J., & Brannan, C. I. (2001) · Genomics · doi:10.1006/geno.2001.6543 · Cited by 204
Meng, L., Person, R. E., & Beaudet, A. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds130 · Cited by 202
Self-citationMolecular and Clinical Aspects of Angelman Syndrome
Dagli, A. I., Buiting, K., & Williams, C. A. (2011) · Molecular Syndromology · doi:10.1159/000328837 · Cited by 165
Meng, L., Person, R. E., Huang, W., Zhu, P. J., Costa-Mattioli, M., & Beaudet, A. L. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1004039 · Cited by 162
Self-citationBehavioral deficits in an Angelman syndrome model: Effects of genetic background and age
Huang, H., Burns, A. J., Nonneman, R. J., Baker, L. K., Riddick, N. V., Nikolova, V. D., Riday, T. T., Yashiro, K., Philpot, B. D., & Moy, S. S. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.052 · Cited by 155
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler, M., Stecker, K., & Bennett, C. F. (1997) · PubMed · Cited by 151
Self-citationA candidate model for angelman syndrome in the mouse
Cattanach, B. M., Barr, J. A., BEECHEY, C. V., Martin, J. E., Noebels, J. L., & Jones, J. B. (1997) · Mammalian Genome · doi:10.1007/s003359900479 · Cited by 90
Allensworth, M. L., Saha, A., Reiter, L. T., & Heck, D. H. (2011) · BMC Genetics · doi:10.1186/1471-2156-12-7 · Cited by 46
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., Allen, H., Parad, R., Johnson, S., Vivo, D. C. D., Norris, D. A., et al. (2013) · Neurology · doi:10.1212/wnl.80.7_supplement.s36.002 · Cited by 10
Cited by
Long Noncoding RNAs in Cancer Pathways
Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 2,992
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
The functions and unique features of long intergenic non-coding RNA
Ransohoff, J. D., Wei, Y., & Khavari, P. A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.104 · Cited by 1,330
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Metadata
- Authors
- Meng, L., Ward, A. J., Chun, S., Bennett, C. F., Beaudet, A. L., & Rigo, F.
- Venue
- Nature
- Published
- 2014-12-01
- Volume
- 518
- Issue
- 7539
- Pages
- 409-412
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985567838
- Cited by
- 518
- References
- 26
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.